VivoSim Labs (VIVS) FCF Margin Growth (3y) (2014 - 2026)
VivoSim Labs (VIVS) FCF Margin Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5,426.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9,545.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4,612.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1,850.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 14,060.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -3,088.00 |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | -1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.09 Mn |
| Mar 31, 2026 | -275,083.00 |
| Dec 31, 2025 | -649,119.00 |
| Sep 30, 2025 | -553,766.00 |
| Mar 31, 2025 | -388,393.00 |
| Dec 31, 2022 | -215,932.00 |
| Sep 30, 2022 | -261,466.00 |
| Mar 31, 2022 | 64,653.00 |
| Dec 31, 2019 | 46,978.00 |
| Sep 30, 2019 | 7,566.00 |
| Jun 30, 2019 | 7,146.00 |
| Mar 31, 2019 | 69,520.00 |
| Dec 31, 2018 | 164,666.00 |
| Sep 30, 2018 | 254,395.00 |
| Jun 30, 2018 | 140,895.00 |
| Mar 31, 2018 | 182,448.00 |
| Dec 31, 2017 | 240,913.00 |
| Sep 30, 2017 | 253,837.00 |
| Jun 30, 2017 | 256,222.00 |
| Sep 30, 2016 | 2.75 Mn |